Lupin is currently trading at Rs. 634.70, up by 57.90 points or 10.00% from its previous closing of Rs. 579.20 on the BSE.The scrip opened at Rs. 580.30 and has touched a high and low of Rs. 637.10 and Rs. 578.60 respectively. So far 48069 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 882.15 on 02-May-2019 and a 52 week low of Rs. 505.00 on 13-Mar-2020.Last one week high and low of the scrip stood at Rs. 637.10 and Rs. 536.80 respectively. The current market cap of the company is Rs. 27859.38 crore.The promoters holding in the company stood at 46.93%, while Institutions and Non-Institutions held 38.99% and 13.80% respectively.Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad, India facility. The inspection for the facility was carried out by the USFDA between February 10, 2020 and February 14, 2020 and concluded with no observations.Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin is currently trading at Rs. 560.00, up by 13.00 points or 2.38% from its previous closing of Rs. 547.00 on the BSE.The scrip opened at Rs. 564.00 and has touched a high and low of Rs. 573.65 and Rs. 536.80 respectively. So far 45857 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 882.15 on 02-May-2019 and a 52 week low of Rs. 505.00 on 13-Mar-2020.Last one week high and low of the scrip stood at Rs. 631.95 and Rs. 536.80 respectively. The current market cap of the company is Rs. 25716.70 crore.The promoters holding in the company stood at 46.93%, while Institutions and Non-Institutions held 38.99% and 13.80% respectively.Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Inhalation Research Center located at Coral Springs, Florida. The facility was inspected by the USFDA, between February 19, 2020 and February 26, 2020, on behalf of the U.K. MHRA for Lupin’s generic Fostair application to the U.K. MHRA. Lupin’s Inhalation Research Center at Coral Springs, Florida, inaugurated in August 2015, focuses on research and development of respiratory products for the treatment of asthma, chronic obstructive pulmonary diseases and other respiratory ailments.Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin is currently trading at Rs. 652.95, up by 1.80 points or 0.28% from its previous closing of Rs. 651.15 on the BSE.The scrip opened at Rs. 655.00 and has touched a high and low of Rs. 659.40 and Rs. 645.75 respectively. So far 22358 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 882.15 on 02-May-2019 and a 52 week low of Rs. 621.00 on 02-Mar-2020.Last one week high and low of the scrip stood at Rs. 685.65 and Rs. 644.30 respectively. The current market cap of the company is Rs. 29716.68 crore.The promoters holding in the company stood at 46.93%, while Institutions and Non-Institutions held 38.99% and 13.80% respectively.Lupin has won the coveted India Pharma Leader Award at the India Pharma 2020 and India Medical Device 2020 conference. This award acknowledges company’s contributions toward strengthening the Indian Pharmaceuticals Market and recognizes its all-round performance.This was the 5th edition of the event organized by FICCI in collaboration with the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. The event theme focused on ‘Clarity on Changing Regulatory Scenarios’ and witnessed participation of more than 1,200 delegates from all over India.Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Net sales declined -12.19%  to  Rs. 27159.00 million from Rs. 30928.00 millions.The Net Loss for the quarter ended December 2019 is Rs. -814.70 millions as compared to Net Profit of Rs. 1418.20 millions of corresponding quarter ended December 2018Operating Profit reported a sharp decline to 4856.20 millions from 8195.60 millions in the corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201912 201812 % Var 201912 201812 % Var 201903 201803 % Var Sales 27159.00 30928.00 -12.19 85420.60 83844.60 1.88 113563.20 100881.80 12.57 Other Income 868.00 389.90 122.62 2720.60 4143.40 -34.34 2913.40 1311.20 122.19 PBIDT 4856.20 8195.60 -40.75 19374.80 21884.90 -11.47 31441.20 22169.80 41.82 Interest 189.10 99.80 89.48 412.10 274.80 49.96 354.70 332.40 6.71 PBDT 866.80 4673.60 -81.45 11370.60 18187.90 -37.48 27686.70 21837.40 26.79 Depreciation 1322.10 1083.10 22.07 3939.70 3174.10 24.12 4263.00 3898.10 9.36 PBT -455.30 3590.50 -112.68 7430.90 15013.80 -50.51 23423.70 17939.30 30.57 TAX 359.40 2172.30 -83.46 2408.30 5053.30 -52.34 8035.40 4492.70 78.85 Deferred Tax -162.40 158.20 -202.65 -110.30 178.80 -161.69 85.40 627.00 -86.38 PAT -814.70 1418.20 -157.45 5022.60 9960.50 -49.57 15388.30 13446.60 14.44 Equity 905.80 904.80 0.11 905.80 904.80 0.11 905.00 904.20 0.09 PBIDTM(%) 17.88 26.50 -32.52 22.68 26.10 -13.10 27.69 21.98 25.98

Lupin is currently trading at Rs. 732.90, up by 10.55 points or 1.46% from its previous closing of Rs. 722.35 on the BSE.The scrip opened at Rs. 730.00 and has touched a high and low of Rs. 733.00 and Rs. 723.50 respectively. So far 1178 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 882.15 on 02-May-2019 and a 52 week low of Rs. 646.20 on 07-Oct-2019.Last one week high and low of the scrip stood at Rs. 739.00 and Rs. 699.00 respectively. The current market cap of the company is Rs. 32719.89 crore.The promoters holding in the company stood at 46.93%, while Institutions and Non-Institutions held 38.99% and 13.80% respectively.Lupin has received approval for its Leflunomide Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Arava Tablets, 10 mg and 20 mg, of Sanofi-Aventis. The product would be manufactured at Lupin`s Pithampur (Unit 1) facility, India.Leflunomide Tablets USP, 10 mg and 20 mg, are indicated for the treatment of adults with active rheumatoid arthritis (RA). Leflunomide Tablets USP (RLD: Arava Tablets) had an annual sales of approximately $44 million in the U.S. (IQVIA MAT December 2019).Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin is currently trading at Rs. 733.80, up by 1.20 points or 0.16% from its previous closing of Rs. 732.60 on the BSE.The scrip opened at Rs. 734.00 and has touched a high and low of Rs. 739.95 and Rs. 728.00 respectively. So far 13899 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 887.70 on 04-Feb-2019 and a 52 week low of Rs. 646.20 on 07-Oct-2019.Last one week high and low of the scrip stood at Rs. 770.00 and Rs. 728.00 respectively. The current market cap of the company is Rs. 33168.63 crore.The promoters holding in the company stood at 46.93%, while Institutions and Non-Institutions held 38.99% and 13.80% respectively.Lupin’s corporate social responsibility (CSR) arm -- Lupin Foundation has won the prestigious Indian Drug Manufacturers` Association (IDMA) Corporate Citizen award 2019, at the IDMA 58th Annual Day Celebrations held in Mumbai on January 18, 2020. The company was conferred this award in the CSR category `Initiative towards Agriculture,` for its beekeeping project that has directly benefitted nearly 4000 families. Beekeeping has become a massive programme in the district and provided employment and alternative source of income for farmers.Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin is currently trading at Rs. 779.25, up by 4.30 points or 0.55% from its previous closing of Rs. 774.95 on the BSE.The scrip opened at Rs. 776.35 and has touched a high and low of Rs. 780.60 and Rs. 770.10 respectively. So far 11755 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 887.70 on 04-Feb-2019 and a 52 week low of Rs. 646.20 on 07-Oct-2019.Last one week high and low of the scrip stood at Rs. 780.10 and Rs. 759.05 respectively. The current market cap of the company is Rs. 35034.60 crore.The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.99% and 14.05% respectively.Lupin’s Ankleshwar facility has won the gold award at the 9th annual conference on quality management, organised by the American Society for Quality (ASQ) at Ahmedabad on November 22, 2019. The nomination case study submitted for this award summarised the transformation project to improve the yield and quality of company’s Cefadroxil products. This is the fourth consecutive year that Lupin`s Ankleshwar facility has won the Gold Award from the American Society for Quality.This year company`s nomination highlighted the key outcomes of its ‘Cefadroxil Yield and Quality Improvement’ project, in the past three years, the company won the award for projects that focused on ethambutol yield improvement (2018), 7AE yield improvement (2017) and 7ACCA yield improvement (2016).Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupinis currently trading at Rs. 772.50, up by 1.80 points or 0.23% from its previous closing of Rs. 770.70 on the BSE.The scrip opened at Rs. 771.10 and has touched a high and low of Rs. 777.25 and Rs. 769.00 respectively. So far 12956 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 887.70 on 04-Feb-2019 and a 52 week low of Rs. 646.20 on 07-Oct-2019.Last one week high and low of the scrip stood at Rs. 777.25 and Rs. 745.30 respectively. The current market cap of the company is Rs. 34971.64 crore.The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.99% and 14.05% respectively.Lupin has collaborated with the American College of Gastroenterology (ACG) for a new initiative ‘The Best of ACG’. Under the terms of the agreement, ACG will take the best education materials from the ACG conference and will present it in Kolkata, Bangalore and Delhi in January 2020. Through this initiative, Lupin aims to bring in global educational material and provide access to latest developments in the field of gastroenterology in India.Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin is currently trading at Rs. 772.00, up by 5.90 points or 0.77% from its previous closing of Rs. 766.10 on the BSE.The scrip opened at Rs. 756.10 and has touched a high and low of Rs. 774.75 and Rs. 756.10 respectively. So far 41712 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 887.70 on 04-Feb-2019 and a 52 week low of Rs. 646.20 on 07-Oct-2019.Last one week high and low of the scrip stood at Rs. 774.75 and Rs. 745.30 respectively. The current market cap of the company is Rs. 34788.26 crore.The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.99% and 14.05% respectively.Lupin has launched Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, having received an approval from the United States Food and Drug Administration (USFDA) earlier. The company’s Doxercalciferol Injection, is the therapeutic generic equivalent of Sanofi Genzyme’s Hectorol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials. It is indicated for the treatment of secondary hyperparathyroidism in adult patients with CKD on dialysis. Doxercalciferol Injection (RLD: Hectorol) had an annual sales of approximately $132 million in the U.S. (IQVIA MAT October 2019). Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin is currently trading at Rs. 762.15, up by 8.15 points or 1.08% from its previous closing of Rs. 754.00 on the BSE.The scrip opened at Rs. 755.00 and has touched a high and low of Rs. 764.80 and Rs. 754.10 respectively. So far 23365 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 887.70 on 04-Feb-2019 and a 52 week low of Rs. 646.20 on 07-Oct-2019.Last one week high and low of the scrip stood at Rs. 764.80 and Rs. 741.15 respectively. The current market cap of the company is Rs. 34577.71 crore.The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.99% and 14.05% respectively.Lupin’s subsidiary--Nanomi B.V. has completed the divestiture of the entire stake (99.82%) in Kyowa Pharmaceutical Industry (Kyowa) to Unison Capital Partners IV, LPS and Unison Capital Partners IV (F). L.P. (collectively referred to as ‘Unison’), pursuant to the satisfactory completion of all customary closing conditions. The divestiture which valued Kyowa at an Enterprise Value of JPY 57,361 million, was announced on November 11, 2019 and approved by Lupin’s shareholders.Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin is currently trading at Rs. 773.00, up by 2.25 points or 0.29% from its previous closing of Rs. 770.75 on the BSE.The scrip opened at Rs. 776.10 and has touched a high and low of Rs. 781.65 and Rs. 767.20 respectively. So far 41937 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 905.90 on 04-Dec-2018 and a 52 week low of Rs. 646.20 on 07-Oct-2019.Last one week high and low of the scrip stood at Rs. 787.65 and Rs. 740.70 respectively. The current market cap of the company is Rs. 34969.24 crore.The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.99% and 14.05% respectively.Lupin has launched ‘ADHERO’, a new connected smart device for metered-dose inhalers. This first-of-its-kind device is designed to help patients with chronic respiratory diseases track their MDI usage and facilitate improved adherence to therapy. The new device, ADHERO, is designed to improve patient adherence to therapy.ADHERO is a bluetooth-enabled, reusable smart device which attaches to the top of a MDI. With built-in sensors, the device tracks the patient`s daily medication usage and consumption patterns. Patients can access this information by connecting their ADHERO device to the ‘MyAdhero’ app on their smartphones. The app is also equipped to send reminders, provide contextual health alerts based on factors like Air Quality Index (AQI) at the patient`s current location and enable visual analytics. Physicians too can access patient-related information and medication tracking data through the patient dashboard portal as well as through the app.Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin is currently trading at Rs. 748.00, up by 1.70 points or 0.23% from its previous closing of Rs. 746.30 on the BSE.The scrip opened at Rs. 747.00 and has touched a high and low of Rs. 754.35 and Rs. 740.70 respectively. So far 24772 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 905.90 on 04-Dec-2018 and a 52 week low of Rs. 646.20 on 07-Oct-2019.Last one week high and low of the scrip stood at Rs. 759.35 and Rs. 721.10 respectively. The current market cap of the company is Rs. 33785.33 crore.The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.99% and 14.05% respectively.Lupin has launched Potassium Chloride (KCI) for Oral Solution USP, 20 mEq, having received an approval from the United States Food and Drug Administration (USFDA) earlier.The company’s Potassium Chloride for Oral Solution USP, 20 mEq, is the generic equivalent of Pharma Research Software Solution, LLC`s Potassium Chloride for Oral Solution USP, 20 mEq, and is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.Potassium Chloride for Oral Solution USP, 20 mEq, had an annual sales of approximately $90 million in the U.S. (IQVIA MAT September 2019).Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.